

Short Report

Prevalence of radiologically isolated syndrome in a pediatric population-based cohort: A longitudinal description of a rare diagnosis

CL de Mol* , AL Bruijstens* , PR Jansen, MHG Dremmen, YYM Wong, A van der Lugt, TJH White and RF Neuteboom

Abstract

Background: Radiologically isolated syndrome (RIS) is typified by multiple sclerosis (MS)-like lesions on imaging, without clinical MS symptoms. The prevalence of pediatric RIS is largely unknown.

Objective: The objective of the study is to provide an estimated RIS prevalence in a population-based cohort of children.

Methods: We used data from the Generation R study to identify the childhood RIS prevalence.

Results: In 5238 participants, only one RIS case was identified (prevalence: 0.02%; 95% confidence interval (CI): 0.00–0.11). During a 62-month follow-up, imaging examinations showed accrual of new focal demyelinating lesions; however, no clinical MS symptoms occurred.

Conclusions: This study shows that the occurrence of RIS in children from the general population is rare.

Keywords: Radiologically isolated syndrome, epidemiology, prevalence, pediatrics, case reports, multiple sclerosis

Date received: 28 October 2020; revised: 17 December 2020; accepted: 28 December 2020.

Introduction

Radiologically isolated syndrome (RIS) is defined as the presence of demyelinating lesions, suggestive of multiple sclerosis (MS) without occurrence of clinical MS symptoms.¹ It is reported in 0.1%–0.7% of adults who underwent brain magnetic resonance imaging (MRI) for complaints not typically compatible with MS (e.g. migraine).² Within 5–10 years, between one-third and half of RIS cases are diagnosed with MS, with children showing earlier fulfillment of the diagnostic criteria.^{3–5} Although knowledge of RIS in children is increasing and specific pediatric diagnostic criteria have been proposed, data on RIS prevalence in childhood remain scarce.^{4,6,7}

Here, we provide information on pediatric RIS prevalence using a large population-based birth cohort study and describe the follow-up of identified cases.

Methods

For the current study, we investigated MRI data from children enrolled in the Generation R Study.⁸ Three waves of MRI examinations were performed

within this population-based cohort: phase 1: a subgroup of children between the ages of 6 and 10,⁹ the whole study group in phase 2: children around 9 years,¹⁰ and phase 3: children around 13 years. Participants were imaged with a 3T MRI scanner: the first subgroup (6–10 years) with an MR750 Discovery MRI scanner and the other two groups (around 9 and 13 years) with an MR750w Discovery scanner (General Electric, Milwaukee, WI, USA). The imaging protocol encompassed, among others, a coronal 3-dimensional (3D) T₁-weighted sequence, sagittal 3D T₂-weighted sequence, and axial spin-echo diffusion-weighted sequence. No gadolinium was administered due to the population-based design of the study. Incidental findings were rated by a team of researchers and neuroradiologists as previously described.¹¹ RIS was assessed with adult Okuda criteria and pediatric criteria proposed by the PARIS consortium.^{1,4}

Parents or legal representatives provided written informed consent of all study participants within the Generation R study. Identified RIS cases provided additional informed consent for the usage of clinical

Multiple Sclerosis Journal

1–4

DOI: 10.1177/
1352458521989220

© The Author(s), 2021.



Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:

RF Neuteboom
Erasmus MC-Sophia, Room
SK-1210, PO Box 2060,
3015 GD Rotterdam, 3000
CA, The Netherlands.
r.neuteboom@erasmusmc.nl

AL Bruijstens
YYM Wong
RF Neuteboom
Department of Neurology,
MS Center ErasMS,
Erasmus MC University
Medical Center Rotterdam,
Rotterdam, The Netherlands

CL de Mol
Department of Neurology,
MS Center ErasMS,
Erasmus MC University
Medical Center Rotterdam,
Rotterdam, The Netherlands
The Generation R Study
Group, Erasmus MC
University Medical Center
Rotterdam, Rotterdam, The
Netherlands

PR Jansen
Department of Complex
Trait Genetics, Center
for Neurogenetics and
Cognitive Research,
Amsterdam Neuroscience,
Amsterdam UMC,
Amsterdam, The Netherlands
Department of Clinical
Genetics, Amsterdam UMC,
Amsterdam, The Netherlands

TJH White
Department of Child and
Adolescent Psychiatry,
Erasmus MC University
Medical Center Rotterdam,
Rotterdam, The Netherlands
Department of Radiology
and Nuclear Medicine,
Erasmus MC University
Medical Center Rotterdam,
Rotterdam, The Netherlands

MHG Dremmen
The Generation R Study
Group, Erasmus MC
University Medical Center
Rotterdam, Rotterdam, The
Netherlands Department
of Radiology and Nuclear
Medicine, Erasmus MC
University Medical Center
Rotterdam, Rotterdam, The
Netherlands

A van der Lugt
 Department of Radiology
 and Nuclear Medicine,
 Erasmus MC University
 Medical Center Rotterdam,
 Rotterdam, The Netherlands

*Authors contributed equally
 to this manuscript

data. The Medical Ethical Committee of the Erasmus Medical Center approved the study protocol.

Results

After excluding overlapping subjects, 5238 participants had MRI scans of sufficient quality to be rated for incidental findings. Participants’ descriptive characteristics of different waves are shown in Table 1.

One participant showed white matter abnormalities fulfilling the adult Okuda and proposed pediatric PARIS criteria for RIS.^{1,4} This resulted in a general RIS prevalence of 0.019% (95% confidence interval (CI): 0.00–0.11) and a wave-specific prevalence of 0.024% (95% CI: 0.00–0.13) between the ages of 9 and 11 years (phase 2; Table 1).

The boy described above was scanned at the age of 11. His first MRI scan showed multiple (>9) well-circumscribed white matter lesions, including several periventricular lesions, intracallosal lesions, and an infratentorial lesion, in addition to T1-hypointense lesions with unknown gadolinium enhancement status (Figure 1).

This Dutch patient (Moroccan descent) was examined at the Dutch pediatric MS center at the age of 12. At the time of the first scan, he had no history of clinical events. However, just 2 months prior to the clinical assessment, he experienced a vertigo episode for a maximum of 7 days. No clinical care was sought out at the time of the symptoms, and at the moment of examination, these had fully recovered. During neurological assessment, no abnormalities were identified; Expanded Disability Status Scale score was 0, urological assessment, including uro-flowmetry, and visual evoked potential examination were normal. A new clinical MRI scan shortly after this clinical assessment, 22 months after the first scan, showed new white matter lesions, but no gadolinium enhancement (Figure 1). No new infratentorial lesions were observed that could account for the vertigo episode. Additional spinal cord MRI showed several cervical lesions. Further investigations showed no indication for other diagnoses, including negative blood test results for aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Through genotyping, the patient was found to have heterozygosity of HLA-DRB1*15:01. There was evidence of a remote Epstein–Barr virus infection (serum IgG antibodies against EBNA1 and VCA) and vitamin D level in serum was low (31 nmol/L, normal reference: 50–120 nmol/L).

Follow-up clinical MRI scans showed new lesions 1 and 3 years after the first clinical assessment, including

Table 1. Participants’ descriptive characteristics throughout the Generation R MRI study waves.

	Phase 1 (n = 1070)	Phase 2 (n = 4092)	Phase 3 (n = 3545)	Total ^a (N = 5238)
Age at scan, years, median (IQR)	7.96 (7.08–8.57)	9.94 (9.76–10.29)	13.82 (13.58–14.27)	NA
Male, n (%)	572 (53.5)	2036 (49.8)	1699 (47.9)	2592 (49.5)
Reported ethnicity				
Dutch	726 (67.9)	2398 (58.6)	2137 (60.3)	3061 (58.4)
Western	78 (7.3)	358 (8.7)	322 (9.1)	465 (8.9)
Non-Western	266 (24.9)	1250 (30.5)	1019 (28.7)	1598 (30.5)
Unknown	0 (0.0)	86 (2.1)	67 (1.9)	114 (2.2)
Presence of maternal MS, n (%)	1/939 (0.11)	6/3344 (0.18)	4/2956 (0.14)	6/4485 (0.13)
Presence of paternal MS, n (%)	1/744 (0.13)	3/2674 (0.11)	2/2404 (0.08)	3/3477 (0.09)
EBV-seropositivity, n (%)	378/742 (50.9)	1274/2624 (48.6)	1138/2308 (49.3)	1695/3344 (50.7)
Serum vitamin D levels, nmol/L, median (IQR)	65.0 (45.1–82.9)	67.0 (49.0–83.1)	66.0 (48.4–82.4)	65.7 (47.9–82.0)
RIS cases identified, n	0	1	0	1
Observed RIS prevalence, % (95% CI)	0.000 (NA)	0.024 (0.00–0.13)	0.000 (NA)	0.019 (0.00–0.11)

IQR: interquartile range; NA: not applicable; MS: multiple sclerosis; RIS: radiologically isolated syndrome; CI: confidence interval; EBV: Epstein–Barr virus.
^aNon-overlapping subjects from phases 1, 2, and 3.




Figure 1. MR images at baseline and follow-up. (a) One coronal T₁-weighted and two sagittal T₂-weighted MR images from the brain imaging protocol of the Generation R Study, belonging to the 11-year-old identified male RIS case. The coronal image shows periventricular T₁-hypointense white matter lesions in both the right and left parietal lobe. The sagittal T₂-weighted images demonstrate additional intracallosal and subcortical T₂-hyperintense white matter lesions. (b) Sagittal T₂-weighted fluid-attenuated inversion recovery (FLAIR) and axial T₂-weighted MR images of the same patient at follow-up brain imaging (22 months later). The T₂ FLAIR sagittal images show hyperintense lesions in the periventricular white matter of the supratentorial brain. These white matter lesions were new in comparison with the previous baseline MR examination. The axial T₂-weighted image shows the infratentorial hyperintense white matter lesion in the right cerebellar hemisphere.

gadolinium enhancement. At the time of last follow-up, 62 months, the patient had not experienced any clinical event. Till now, no immunomodulatory treatment has been started.

Discussion

In this study, we show that the RIS prevalence in a cohort of developing children between the ages of 6 and 16 is low (0.02%). This is in line with another study in a pediatric MRI cohort of 833 participants that also observed only one patient with a suspected demyelinating lesion, although this patient appeared not to fulfill the Okuda and PARIS criteria for RIS.¹²

Compared with the reported prevalence of adult RIS, our observed prevalence of pediatric RIS is low.² This difference in prevalence could be due to the population-based approach in our study and the younger age of our participants. Another possibility is that our reported prevalence might be an underestimation of the RIS prevalence, as no T₂ fluid-attenuated inversion recovery sequence was performed within the Generation R Study, which is optimal for the detection of white matter lesions. Another limitation to our

study is that while we provide an overall prevalence of RIS between ages 6 and 16, the majority of our participants was 10 years or older. We could therefore have been underpowered to detect possible RIS in this younger age group. Nevertheless, the effect of this relative underrepresentation of children aged between 6 and 10 years on the overall RIS prevalence is expected to be limited as pediatric RIS is typically diagnosed at a higher age.^{4,7} In our study, we did not observe the previously reported female overrepresentation in (pediatric) RIS.^{2,4,7} Next to cohort size, this may be due to the even sex distribution in the Generation R study, based on its population-based inclusion.⁸ This could have made our study relatively underpowered to detect the known female overrepresentation in RIS. Compared with the general Dutch population, our study had a relative overrepresentation of non-Western children, due to the multi-ethnic Generation R cohort.⁸ This may have influenced our results, as we have previously observed a higher prevalence of pediatric onset of MS in non-Western children in the Netherlands.¹³

The described patient had not experienced any history of relapsing-remitting clinical symptoms at the time of initial MRI scan and was therefore diagnosed with RIS.

Whether or not disease modifying therapy should be started in RIS patients with new MRI lesions, without clinical neurological events, is controversial.⁶ The subsequent vertigo episode was not objectified, and the second MRI scan did not show explanatory lesions for this possible clinical episode. Although debatable, we chose a close monitoring policy instead of starting immunomodulatory treatment.

To conclude, we observed that prevalence of RIS in a population-based cohort of children is low. As prevalence appears to be lower compared with adults, extrapolation of information from adult studies on RIS to children may not apply. Therefore, standardized follow-up in those rare children with RIS is needed to increase knowledge on the clinical management of these children. Finally, our study shows that pediatric population-based studies on risk factors for RIS and MS would require considerable numbers of participants.

Acknowledgements

We want to thank Dr. M.C.Y. De Wit for her involvement in the clinical care of the patient and for assisting in composing this manuscript.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. R. F. Neuteboom participates in trails with Sanofi Genzyme and Novartis. No other competing interests are present in this current study.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Dutch MS Research Foundation. The general design of the Generation R Study is supported by the Erasmus Medical Center, the Erasmus University Rotterdam, the ZonMw, the NOW, and the Ministry of Health, Welfare, and Sport.

ORCID iDs

CL de Mol  <https://orcid.org/0000-0002-3733-1706>

AL Bruijstens  <https://orcid.org/0000-0002-7990-5894>

References

1. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome.

Neurology. Epub ahead of print 3 March 2009. DOI: 10.1212/01.wnl.0000335764.14513.1a.

2. Granberg T, Martola J, Kristoffersen-Wiberg M, et al. Radiologically isolated syndrome -Incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. *Mult Scler* 2013; 19(3): 271–280.
3. Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. *PLoS One* 2014; 9(3): e90509.
4. Makhani N, Frenay CL, Siva A, et al. Pediatric radiologically isolated syndrome: Clinical and radiological outcomes. *Neurology* 2016; 86. <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L722519>
5. Lebrun-Frenay C, Kantarci O, Siva A, et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. *Ann Neurol* 2020; 88(2): 407–417.
6. Makhani N. Treatment considerations in the radiologically isolated syndrome. *Curr Treat Options Neurol*. Epub ahead of print 3 February 2020. DOI: 10.1007/s11940-020.
7. Makhani N, Lebrun C, Siva A, et al. Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. *Mult Scler J Exp Transl Clin* 2019; 5(1): 2055217319836664.
8. Kooijman MN, Kruithof CJ, van Duijn CM, et al. The Generation R Study: Design and cohort update 2017. *Eur J Epidemiol* 2016; 31(12): 1243–1264.
9. White T, El Marroun H, Nijs I, et al. Pediatric population-based neuroimaging and the Generation R Study: The intersection of developmental neuroscience and epidemiology. *Eur J Epidemiol* 2013; 28(1): 99–111.
10. White T, Muetzel RL, El Marroun H, et al. Paediatric population neuroimaging and the Generation R Study: The second wave. *Eur J Epidemiol* 2018; 33(1): 99–125.
11. Jansen PR, Dremmen M, Van Den Berg A, et al. Incidental findings on brain imaging in the general pediatric population. *N Engl J Med*. Epub ahead of print 19 October 2017. DOI: 10.1056/NEJMc1710724.
12. Sullivan EV, Lane B, Kwon D, et al. Structural brain anomalies in healthy adolescents in the NCANDA cohort: Relation to neuropsychological test performance, sex, and ethnicity. *Brain Imaging Behav* 2017; 11: 1302-1315.
13. de Mol CL, Wong YYM, van Pelt ED, et al. Incidence and outcome of acquired demyelinating syndromes in Dutch children: Update of a nationwide and prospective study. *J Neurol* 2018; 265(6): 1310–1319.